SCHEDULE: Affinity Asset Advisors Discloses 5.5% Stake in Verrica

Affinity Asset Advisors, LLC and Michael Cho have disclosed a 5.5% beneficial ownership stake in Verrica Pharmaceuticals Inc., including shares from warrants.

Summary

• Affinity Asset Advisors, LLC and Michael Cho collectively beneficially own 884,172 shares of Verrica Pharmaceuticals Inc. common stock.
• This ownership represents approximately 5.5% of the outstanding common stock.
• The total includes 176,834 shares issuable upon the exercise of warrants held by Affinity Healthcare Fund, LP.
• The percentage is calculated based on 15,989,861 shares outstanding as of December 1, 2025, plus the warrant shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Verrica Pharmaceuticals Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a specialized healthcare investment firm has taken a significant passive stake in Verrica Pharmaceuticals Inc., indicating potential long-term confidence in the company.

Positives

• A significant institutional investor, Affinity Asset Advisors, and its managing member, Michael Cho, have taken a notable stake in Verrica Pharmaceuticals Inc., potentially signaling confidence in the company's long-term prospects.
• The investment includes warrants, indicating a potential long-term bullish view on the stock's appreciation.

Negatives

• The filing itself does not present any negative financial or operational information about Verrica Pharmaceuticals Inc.

Risks

• The filing does not detail specific risks related to Verrica Pharmaceuticals Inc.'s operations or financial health; it is a disclosure of ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Verrica Pharmaceuticals Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• The filing includes a certification from Affinity Asset Advisors, LLC and Michael Cho stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Verrica Pharmaceuticals Inc.

Industry Context

StockSavvy.ai notes that a 5.5% stake by an investment adviser specializing in healthcare, such as Affinity Asset Advisors, can be interpreted by the market as a vote of confidence in Verrica Pharmaceuticals Inc.'s position within the pharmaceutical industry, particularly given the inclusion of warrants which suggest a long-term perspective.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially influencing stock valuation.
• Company Management: Awareness of a substantial passive investor may influence strategic decisions, though the filing explicitly states no intent to influence control.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Verrica Pharmaceuticals Inc. or the reporting persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Affinity Asset Advisors is a positive indicator of confidence in Verrica Pharmaceuticals Inc., this filing alone does not provide sufficient operational or financial details to warrant a 'buy' recommendation. It primarily signals a passive investment. Investors should 'hold' and await further fundamental updates from the company to assess its performance and future prospects.

Keywords

Verrica Pharmaceuticals Inc., Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Healthcare Fund